培菲康和黄连素联合治疗慢性腹泻的可行性及安全性

目的：评价培菲康联合黄连素治疗慢性腹泻的的临床疗效。方法：选取2011年4月-2012年6月我院门诊收治的慢性腹泻患者99例，随机分为三组，其中A组35例，选用培菲康与黄连素联合治疗，B组33例，仅选用培菲康进行治疗，C组31例，仅选用黄连素进行治疗，3周后观察两组患者临床疗效与不良反应发生情况。结果：A组临床疗效与慢性腹泻缓解时间明显优于其他两组，A组与B组、C组分别比较临床疗效和慢性腹泻缓解时间差异有统计学意义（P〈0．05）；三组均为出现明显的不良反应，比较差异无统计学意义（P〉0．05）。结论：培菲康联合黄连素治疗慢性腹泻的的临床疗效好，能迅速缓解腹泻症状，且安全性高，值得在临床上予以推广。

A feasibility and safety analysis of treating chronic diarrhea with bifico plus berberine

Objective： To evaluate clinical efficacy of bifico plus berberine on chronic diarrhea. Methods： 99 patients were randomly divided into three groups, 35 patients in group A were given bifico plus berberine; 33 cases in group B were given bifico only; 31 cases in group C were given berberine only for treatment, with three weeks of treatment, clinical effects and side effects were observed. Results： Clinical effects and chronic diarrhea remission time in group A was significantly better than other two groups （P〈0.05）, and there were adverse reactions in three groups, but the difference was not statistically significant （P〉0.05）. Conclusion： Bifico plus berberine could quickly relieve clinical symptoms of diarrhea with confirmed effects and safety, and was worthy of clinical promotion.